REGULATORY

Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin

February 14, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A health ministry panel has agreed that the filing of a public knowledge-based application would be appropriate for Novartis Pharma’s long-acting somatostatin analog Sandostatin (octreotide) for an additional indication of “improvement of hypoglycemic symptoms associated with congenital hyperinsulinism (CHI) unresponsive…

To read the full story

Sandostatin Now Eligible for Health Coverage for Congenital Hyperinsulinemia
March 4, 2020

REGULATORY

Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026
Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…